Drug Database
TJ

TJ-15 (OGT)

✓ Approved

Tsumura · therapeutic agent

What is TJ-15?

TJ-15 is a therapeutic agent developed by Tsumura. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesOGT
CompanyTsumura
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Tsumura

Therapeutic Indications

TJ-15 is developed for 5 unique indications across 5 therapeutic areas.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersEczema✓ Approved
Gastrointestinal disordersGastritis✓ Approved
Vascular disordersHypertension✓ Approved
Psychiatric disordersObsessive-compulsive disorder✓ Approved
Nervous system disordersCerebral cyst haemorrhage✓ Approved

Related Research Articles

PubMedAnesthesia and pain medicine2026-08-25

An evaluation of transdermal buprenorphine and transdermal fentanyl patch on quality of recovery-15 and analgesic effect following inguinal hernia surgery: a randomized controlled study.

A Chaitanya Pratyusha CP, Ch Rama Krishna Prasad RKP, Garre Sandeep S, S Kalyani Sdl KS et al.

Effective postoperative analgesia is essential for optimizing recovery and patient satisfaction after inguinal hernia surgery. Therefore, we compared transdermal buprenorphine and fentanyl patches with conventional analgesia for pain control and quality of recovery-15 (QoR-15). In this prospective, randomized study 150 patients classified as American Society of Anesthesiologists (ASA) I-III scheduled for elective open inguinal hernia repair were randomized into three groups; (n=50 each) Group B (buprenorphine 10 µg/h patch), Group F (fentanyl 25 µg/h patch), and Group C (intravenous paracetamol and tramadol). Patches were applied 12 h preoperatively. The primary outcome was visual analog scale (VAS) pain score, assessed at 1, 6, 12, and 24 h. Secondary outcomes included QoR‑15 scores and rescue‑analgesic requirements. Statistical analysis was performed using the Kruskal-Wallis and Mann-Whitney U tests with Bonferroni correction. Baseline demographic characteristics and perioperative hemodynamic parameters were comparable across groups. Median postoperative VAS scores at 6, 12, and 24 h were significantly lower in both transdermal groups than in the control group. QoR-15 scores at 24 h were 124 (122-125) (C), 127 (125-129) (F), and 133 (131-134) (B), at 48 h were 129 (128-130), 136 (134-138), and 137 (135-139) for Groups C, F, and B, respectively (P = 0.001). Transdermal buprenorphine and fentanyl provided effective postoperative analgesia and were associated with improved quality of recovery compared with standard analgesia. Buprenorphine showed a significant advantage over fentanyl in QoR-15 at 24 h, however, this difference was not significant at 48 h.

PMID 42638571
Read full article →
PubMedStrabismus2026-08-25

Distance-dependent changes in deviation control after alternate occlusion therapy in children with intermittent exotropia: a retrospective pilot study.

Narita Ikumi I, Wakayama Akemi A, Takezawa Yuko Y, Shiraishi Yukari Y et al.

Purpose: To evaluate distance-dependent changes in deviation control after alternate occlusion therapy in children with intermittent exotropia (IXT). Methods: This study included 15 patients (6 males and 9 females) aged 4 to 6 years who had undergone alternate occlusion therapy for more than 2 months at the Department of Ophthalmology, Kindai University Hospital between June 2022 and December 2023. Alternate occlusion was performed at a ratio of 1:1 or 2:1, and daily occlusion time was set to 4 to 6 hours. Patients' control was evaluated at 30 cm, 1, 2, 3, 4, and 5 m and classified using Kushner's 4-grade (Excellent, Good, Fair, Poor) classification method (2019). In this study, an excellent or good level of control was considered favorable and otherwise unfavorable. Control was evaluated at the start (baseline) and the end of the occlusion therapy. Factors for control improvement including the initial age, the occlusion duration, and the initial deviation angle were also analyzed. We further investigated if patients' control varied with viewing distance by examining the viewing distance at which phoria could be maintained. Results: Of 15, 6 (40.0%) patients had unfavorable near control at baseline and 5 (83.3%) of them significantly improved control to a favorable level after occlusion (95% CI: 0.06-0.61). At distance, all 15 patients had unfavorable control at baseline and 5 (33.3%) patients significantly improved control to a favorable level after occlusion therapy (95% CI: 0.09-0.57). Logistic regression analysis revealed no significant factors influencing patients' control improvement. Of 15, 14 patients could be examined for phoria maintenance at all viewing distances and 11 (78.6%) patients showed phoria maintenance in a significantly extended viewing distance after occlusion therapy (p < .01, Wilcoxon signed-rank test).In addition, the proportion of patients maintaining phoria significantly increased at 1 m and 2 m (p = .031 for both). Conclusion: Alternate occlusion therapy was associated with improved deviation control and an extension of the viewing distance over which phoria could be maintained in children with IXT, suggesting a distance-dependent pattern of improvement progressing from near to distance rather than uniformly across distances.

PMID 42639961
Read full article →
PubMedNature human behaviour2026-08-25

Trial-by-trial fluctuations in decision criterion shape confidence.

Vloeberghs Robin R, Navarrete Orejudo Lara L, Urai Anne E AE, Desender Kobe K

Many decisions are accompanied by confidence. One influential view couched within signal detection theory views confidence as the distance between a decision variable and a static decision criterion. However, recent work suggests that the criterion undergoes trial-by-trial fluctuations. Here, combining theory and model simulations, we predict that fluctuations in the decision criterion shape confidence. In 15 datasets, trial-by-trial estimates of the decision criterion were obtained with the hierarchical model for fluctuations in criterion. Across datasets, we confirmed our pre-registered hypothesis that confidence is shaped by a single-trial criterion state. This effect was found in 14 out of 15 datasets, indicating a robust pattern across a variety of paradigms and confidence scales. Beyond self-reports, the effect was also observed in reaction times, pupil-linked arousal and a neural signature of confidence. Our results show that variability in confidence, often treated as noise, actually reflects genuine sensitivity to the current state of the (fluctuating) decision criterion.

PMID 42637913
Read full article →
PubMedFrontiers in tuberculosis2026-08-25

Evaluation of host-immune biomarker signatures as multiplex qPCR diagnostic assays: a pilot study toward meeting WHO target product profiles for TB diagnosis in India.

Garlant Harriet N HN, Ellappan Kalaiarasan K, Joseph Noyal Mariya NM, Turner Carrie C et al.

Tuberculosis (TB) remains the leading cause of death from a single infectious agent. Current diagnostic tools are limited, especially in low-resource settings. The World Health Organization's (WHO) Target Product Profiles (TPPs) call for rapid, non-sputum-based diagnostics with high sensitivity and specificity. This study evaluates our previously published TB-associated host-immune biomarkers alongside small-size signatures from other studies, in our previously published non-human primate (NHP) TB infection study dataset (GSE76703) and two previously published human datasets (GSE144127, GSE42834), which include other disease group comparators, including sarcoidosis. These were also evaluated in a small-scale, exploratory qPCR pilot study to assess the feasibility of implementing these previously validated signatures in a South Indian TB patient cohort, comparing their diagnostic performance against WHO TPP criteria. Twenty-six genes from published signatures (INDUK, Roe1/Roe3, Sweeney3, RISK6) were analyzed in these NHP and human datasets, using network and machine learning approaches, prior to exploratory evaluation using single and multiplex qPCR assays. These were tested using peripheral blood sample RNAs from pulmonary TB (PTB) (n = 15) and extrapulmonary TB (EPTB) (n = 15) patients and high-incidence controls (n = 15). The diagnostic performance of biomarkers, prior signatures, and novel promising combinations were assessed against WHO TPPs for triage and confirmatory tests. Several biomarker signatures successfully distinguished active TB ((ATB) PTB and EPTB combined) from controls. The minimal INDUK signature (GBP1 + IFIT3) met the optimal TPP criteria for both triage and confirmatory testing for PTB (100% sensitivity and specificity, area under the receiver operating characteristic curve (AUROC:1)) and achieved the 80% sensitivity, 100% specificity threshold for EPTB (AUROC: 0.92 CI: 0.8261-1.00). Combined signatures incorporating genes from INDUK, Roe1, and Sweeney3 further improved diagnostic accuracy for ATB overall (AUROC: 0.98 95% CI: 0.9472-1.00). This preliminary pilot study demonstrates successful evaluation of biomarker signatures as diagnostic qPCR assays for TB diagnosis and, to our knowledge, is the first study to demonstrate the potential for combined host-immune biomarker signatures from different studies that meet WHO TPP benchmarks. These findings support the potential for the development of low-cost, field-adaptable diagnostic tools. Further validation is now under way on a larger cohort of TB patients and controls.

PMID 42638755
Read full article →
PubMedNutricion hospitalaria2026-08-25

Associations of dietary diversity and specific food intake with abnormal sleep duration and sleep quality among older adults in China.

Luo Yang Y, Qin Siyi S, Wang Hongyan H, Liu Linfeng L et al.

to examine associations of dietary diversity and specific food intake with abnormal sleep duration (< 6 h or > 8 h) and sleep quality among older adults in China. this cross-sectional study used data from the 2018 Chinese Longitudinal Healthy Longevity Survey and included 12,760 adults aged ≥ 65 years. A simplified food frequency questionnaire was used to assess 15 food categories and calculate a dietary diversity score (0-15). Sleep duration was classified as normal (6-8 h) or abnormal (< 6 h or > 8 h), and sleep quality was self-rated on a five-point scale. Binary logistic regression was used for abnormal sleep duration and ordinal logistic regression for sleep quality, adjusting for sociodemographic, lifestyle, and health-related factors. each 1-point increase in dietary diversity score was associated with lower odds of abnormal sleep duration (OR 0.935, 95 % CI 0.919-0.951) and higher odds of better sleep quality (OR 1.117, 95 % CI 1.100-1.135). Compared with Q4, Q1 was associated with lower odds of abnormal sleep duration (OR 0.659, 95 % CI 0.588-0.739) and higher odds of better sleep quality (OR 1.804, 95 % CI 1.633-1.994), with significant dose-response relationships (p for trend < 0.001). After false discovery rate correction, higher intake of fresh fruits and vegetables was associated with lower odds of abnormal sleep duration, while higher intake of fresh fruits, eggs, legumes, and nuts was associated with better sleep quality. higher dietary diversity was independently associated with lower odds of abnormal sleep duration and better sleep quality among older adults.

PMID 42639933
Read full article →
PubMedDrug design, development and therapy2026-08-25

Apatinib Inhibits the Metabolic Clearance of Ropivacaine: An in vitro and in vivo Evaluation.

Zhang Weiyi W, Wang Peiqi P, Cai Yaoyao Y, Feng Chengyao C et al.

Ropivacaine, a local anesthetic, is commonly used for surgical local anesthesia and labor analgesia. This study aimed to investigate the effect of apatinib on ropivacaine metabolism in vitro and in vivo, and to elucidate its inhibitory mechanism. Following preliminary screening of 18 candidate drugs, apatinib was selected for further evaluation. An enzymatic reaction system was established using rat liver microsomes (RLM), human liver microsomes (HLM), and recombinant human CYP1A2 (rCYP1A2). The ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed for the simultaneous quantification of ropivacaine and its metabolite, 3-hydroxy ropivacaine. The UPLC-MS/MS method showed good linearity over 2-250 ng/mL for ropivacaine and 1-25 ng/mL for 3-hydroxy ropivacaine, respectively. Both showed intra- and inter-day precision (RSD%) below 15% and accuracy (RE%) within ± 15%. Apatinib inhibited ropivacaine metabolism in RLM, HLM, and rCYP1A2, with half-maximal inhibitory concentration (IC50) values of 0.29, 9.12, and 2.49 μM, respectively. In the RLM metabolic stability assay, apatinib slowed ropivacaine metabolism and reduced its intrinsic clearance (CLint) from 0.14 to 0.04 mL/min/mg. Enzyme kinetic analysis indicated non-competitive inhibition in all systems. In rats, co-administration with apatinib increased the area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax) of ropivacaine by 0.83- and 0.71-fold, respectively, decreased the clearance (CLz/F) by 47.17%. Both in vitro and in vivo results indicated that apatinib inhibited the metabolism of ropivacaine. These findings provided essential reference data for the rational application of ropivacaine in clinical precision dosing regimens.

PMID 42639373
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about TJ-15